Two recent studies reported enhanced survival when combining the KRAS G12C inhibitors with anti-PD-1 immune checkpoint blockade in an immunotherapy sensitive syngeneic KRAS G12C mutant CT26 colon carcinoma subcutaneous tumour model15,16. This evidence concerns the gene KRAS and neoplasm.